New drug aims to calm kidney attack by antibodies
NCT ID NCT07571746
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times
Summary
This study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which is a sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surovatamig
- What this could lead to
- If successful, this could point toward a new treatment option for people with primary membranous nephropathy, potentially reducing protein in the urine and improving kidney function.
- What could go wrong
- This is an early Phase 2 trial with only 43 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNLos Angeles, California, 90022, United States
-
Research Site
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
Research Site
NOT_YET_RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site
NOT_YET_RECRUITINGBethesda, Maryland, 20889, United States
-
Research Site
NOT_YET_RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGHouston, Texas, 77027, United States
-
Research Site
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Research Site
NOT_YET_RECRUITINGIeper, 8900, Belgium
-
Research Site
NOT_YET_RECRUITINGBordeaux, 33076, France
-
Research Site
WITHDRAWNCréteil, 94010, France
-
Research Site
NOT_YET_RECRUITINGLyon, 69009, France
-
Research Site
NOT_YET_RECRUITINGNantes, 44093, France
-
Research Site
NOT_YET_RECRUITINGNîmes, 30029, France
-
Research Site
NOT_YET_RECRUITINGDüsseldorf, 40225, Germany
-
Research Site
NOT_YET_RECRUITINGMünchen, 80336, Germany
-
Research Site
NOT_YET_RECRUITINGBrescia, 25123, Italy
-
Research Site
NOT_YET_RECRUITINGRozzano, 20089, Italy
-
Research Site
NOT_YET_RECRUITINGTorino, 10154, Italy
-
Research Site
WITHDRAWNVerona, 37126, Italy
-
Research Site
NOT_YET_RECRUITINGLodz, 92-213, Poland
-
Research Site
NOT_YET_RECRUITINGBarcelona, 08025, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28041, Spain
-
Research Site
NOT_YET_RECRUITINGLondon, NW3 2PF, United Kingdom
-
Research Site
NOT_YET_RECRUITINGManchester, M13 9WL, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New gel could outperform standard therapy for kidney disease